Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, Bonifacio M, Patriarca A, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Giai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D. Efficace F, et al. Cancer. 2024 Jan;130(2):287-299. doi: 10.1002/cncr.35021. Epub 2023 Oct 6. Cancer. 2024. PMID: 37801052
Addressing financial toxicity in oncology care.
Coughlin SS, Moore JX, Cortes JE. Coughlin SS, et al. Among authors: cortes je. J Hosp Manag Health Policy. 2021 Sep;5:32. doi: 10.21037/jhmhp-20-68. Epub 2021 Sep 25. J Hosp Manag Health Policy. 2021. PMID: 34549166 Free PMC article. No abstract available.
Quizartinib, the next FLT3 inhibitor.
Cortes J. Cortes J. Clin Adv Hematol Oncol. 2023 May;21(5):240-243. Clin Adv Hematol Oncol. 2023. PMID: 37145493 No abstract available.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Erba HP, et al. Among authors: cortes j. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25. Lancet. 2023. PMID: 37116523 Clinical Trial.
Problems in living among breast cancer survivors.
Coughlin SS, Ayyala DN, Cortes JE. Coughlin SS, et al. Among authors: cortes je. Curr Cancer Rep. 2021 Jun 15;3(1):101-109. doi: 10.25082/CCR.2021.01.005. Epub 2021 Apr 16. Curr Cancer Rep. 2021. PMID: 33937867 Free PMC article.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Watts JM, et al. Among authors: cortes je. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. Lancet Haematol. 2023. PMID: 36370742 Clinical Trial.
450 results